Faust Pharmaceuticals: Repurposing, Repositioning and the Route to Market




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Faust Pharmaceuticals: Repurposing, Repositioning and the Route to Market
Released on: October 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this week’s exclusive interview, live from Geneva, Fintan Walton talks to Thomas Seoh, CEO of France’s Faust Pharmaceuticals, a company focused on CNS disorders.
  • Summary
  • Participants
  • Company
In this week’s exclusive interview, live from Geneva, Fintan Walton talks to Thomas Seoh, CEO of France’s Faust Pharmaceuticals, a company focused on CNS disorders. Thomas starts by giving some company background, then talks about the way that Faust focuses on three types of compound – repurposed, repositioned and NCE – and about how the company’s strategy is to raise capital from the first two types to fund the third. The discussion covers the company’s two key compounds and recent issues surrounding their development. In particular, Thomas explains how the company’s strategy around its lead Parkinson’s disease compound, FP0011, has changed following the receipt of an unexpected preclinical safety signal, and how Faust is now seeking funding and a partner to take the compound through to Phase IIb and beyond.
Thomas Seoh has been CEO of Faust Pharmaceuticals since 2006. Before that, he worked at Guilford Pharmaceuticals as Senior Vice President, Corporate and Commercial Development. In this role, he participated in the raising of approximately US$400 M in the capital markets and through corporate partnering transactions; he also led deals in a business or legal capacity with Merck, Pfizer, Aventis, Amgen, Johns Hopkins University, MIT and others, involving assets ranging from research and preclinical stages through to marketed products.
Faust Pharmaceuticals